About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
B
Targeted & Immunotherapy for Esophageal Cancer: Are We There Yet? Is Immune Checkpoint Inhibition Without Chemotherapy a First-Line Option for PD-L1 Expressive Tumors With High CPS?
By
BCM Current Medical and Surgical Management of Esophageal Diseases
FEATURING
Brandon G. Smaglo
By
BCM Current Medical and Surgical Management of Esophageal Diseases
FEATURING
Brandon G. Smaglo
92 views
June 25, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
10:25
Exelixis
Explore the mechanism of Action of a TKI in HCC
Feat.
W. Keiser
Featured Video
20:00
Exelixis
Child-Pugh Classification and its Role in Treatment Decisions in Pat…
Feat.
P. Gholam
Related Content
AUTOPLAY
ON
27:12
Moffitt Cancer Center
Year in Review: Upper GI Cancers
Feat.
R. Kim,
R. Mehta
17:23
Insights from 2024 ASCO® GI Annual Meeting
ASCO® GI 2024 Summary: "Esophageal Squamous Cell Carcinoma Key …
Feat.
R. Kim,
R. Mehta
18:51
Hope for Stomach Cancer
1L Therapy for Stage 4 Gastroesophageal Cancers: The Role of Biomark…
Feat.
D. Catenacci
16:53
Scripps MD Anderson Cancer Center
GC/GEJC/EC Trials - Evolving Landscape and Treatment Guidance
Feat.
J. Hecht
06:53
Insights from 2024 ASCO® GI Annual Meeting
ASCO® GI 2024 Panel Discussion: "SKYSCRAPER-08 Clinical Implica…
Feat.
Y. Janjigian,
S. Cytryn,
S. Klempner
41:38
Dana-Farber Cancer Institute
Let Me Eat: The Road to Reconstructing the Esophagus
Feat.
J. Wee
11:02
ASCO GI 2023 Conference Coverage
ASCO GI 2023 3-Year Follow-Up From CheckMate 649: Nivo + Chemo vs. C…
Feat.
Y. Y. Janjigian
15:47
Integrity Continuing Education
Resectable GEJ Adenocarcinoma: Case Presentation and Expert Panel Di…
Feat.
K. Bever,
R. Voong,
J. Hernandez,
S. Klempner
19:29
Total Health
Case-Based Clinical Updates in GI Cancer: 56 y/o Male With GEJ Adeno…
Feat.
R. Mehta,
M. Tejani,
K. Blue
44:18
Debbie's Dream Foundation
ASCO® 2023 Insights: "What's New in Stomach and Esophageal…
Feat.
S. Klempner
24:45
Total Health
2023 Gastro-Esophageal Update
Feat.
M. Karimi
57:57
Hope for Stomach Cancer
1L Therapy for HER2+ Stage 4 Gastroesophageal Cancers
Feat.
D. Catenacci
31:25
Hope for Stomach Cancer
1L Chemo for Stage 4 Gastroesophageal Cancers: Doublet vs. Triplet
Feat.
D. Catenacci
23:39
OncoAlert
Year in Review: Gastric, Esophageal, & Liver Cancers
Feat.
S. Gill
06:31
ecancer
CheckMate 649 Trial Biomarker Analyses of Nivo + Ipi vs. Chemo for P…
Feat.
Y. Y. Janjigian
28:16
Hope for Stomach Cancer
1L Chemo for Stage 4 Gastroesophageal Cancers
Feat.
D. Catenacci
15:18
Insights from 2024 ASCO® GI Annual Meeting
ASCO® GI 2024 Insights: "Case Presentation on Upper GI Malignan…
Feat.
N. Uboha
24:35
Total Health
Complete Responders vs. Partial or Non-Responders in Esophageal Canc…
Feat.
A. Saeed
51:36
Debbie's Dream Foundation
Newest Advances in IO and Targeted Agents for Gastroesophageal Cancer
Feat.
D. Ilson
14:37
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Randomized, Double-Blind, Placebo-Control…
Feat.
A. Batra
